Cenix, SYGNIS Sign RNAi Research Pact

Cenix BioScience has signed a research agreement with SYGNIS Bioscience to advance the SYGNIS KIBRA project aimed at developing treatments for various forms of dementia.

Cenix will apply its expertise in combining high content screening with gene silencing analyses in cultured human cells, to establish and optimize multi-parametric microscopy-based assays using the Definiens XD image analysis system. Using these assays, Cenix will conduct target validation to prioritize novel therapeutic drug target candidates. Financial terms were not disclosed.

“We are delighted to enter into this new relationship with SYGNIS,” said Dr. Christophe Echeverri, chief executive officer and chief scientific officer of Cenix. “This project, and the many others like it now ongoing here and throughout the industry, continue to confirm the unparalleled power of RNAi-based experimentation for not only discovering but also validating and de-risking new candidate drug targets.”